The Following Characterizes Phase 3 Trials of Drug Development

The following characterizes Phase 3 trials of drug development:

A) Conducted on several thousand patients with specific diseases to determine overall risk-benefit relationships
B) Conducted on a small number of normal volunteers to determine safe dosage range and pharmacokinetic parameters
C) Conducted on animals to determine what potential toxicities exist and at what serum levels those toxicities are manifest
D) Surveillance of a drug after release on the market to determine whether any previously undetected side effects develop after extended use of the drug on large populations
E) Conducted on several hundred patients with specific diseases to determine short-term safety and effectiveness of the drug